Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor SAPT vs DAPT in High Bleeding Risk Patients After DCB
NCT06088433Phase 4Unknown
- Sponsor
- Fuwai Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Fuwai Hospital. Primary endpoint: Major Adverse Cardiovascular Events at 12 months. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on NCT06088433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088433.